News & Updates
Showing Rheumatology articles
Showing
Show Multimedia Only

Izokibep maintains PsA efficacy at 52 weeks
04 Aug 2026
byElvira Manzano
The novel small-protein IL-17 inhibitor izokibep demonstrates durable efficacy and a favourable safety profile over 52 weeks in patients with active psoriatic arthritis (PsA), with sustained improvements in joint, skin, and quality-of-life outcomes in a phase IIB/III study.
04 Aug 2026

Bimekizumab tops risankizumab on ACR50 in psoriatic arthritis
30 Jul 2026
byKanas Chan
Bimekizumab outperformed risankizumab in the American College of Rheumatology ≥50 percent response criteria (ACR50) among patients with active psoriatic arthritis (PsA) in the phase IIIb BE BOLD trial – the first head-to-head PsA study to demonstrate superiority for a joint-focused primary endpoint.
30 Jul 2026






